Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06185764 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
A Phase 1 study of Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 20
- Study locations
NCT06185764: Recruiting Phase 1 study of Myotonic Dystrophy Type 1 (DM1), sponsored by Vertex Pharmaceuticals Incorporated.
NCT06185764 is a Phase 1 study of Myotonic Dystrophy Type 1 (DM1) that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06185764, a Phase 1 study of Myotonic Dystrophy Type 1 (DM1), is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-670
Study Locations (20)
Other
- Wesley Research Institute - Auchenflower
- Neuroscience Clinical Trials Unit, Alfred Brain - Melbourne
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Leuven
- Hopital de Chicoutimi - Chicoutimi
- Altasciences Montreal - Montreal
- McGIll University - Montreal
- University of Ottawa - Ottawa
- CHU Research Centre of Quebec - Québec
- Neuromuscular Reference Center Institute of Myology - Paris
- Ludwig Maximilians Universitaet Muenchen - München
- Centro Clinico NeMO - Milan
- Maastricht University Medical Center - Maastricht
California
- Stanford Neuromuscular Research - San Carlos
Florida
- University of Florida Clinical Research Center - Gainesville
Kansas
- University of Kansas Medical Center - Fairway
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University School of Medicine / St. Louis Children's Hospital - St Louis
North Carolina
- Wake Forest Baptist Health - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-12-22 |
| Phase | Phase 1 |
What NCT06185764 shows while recruiting
NCT06185764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Myotonic Dystrophy Type 1 (DM1) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06185764 names 20 study sites across 9 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06185764 about?
NCT06185764 is a clinical study titled "A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
What is the current status of trial NCT06185764?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2024-02-20. Estimated completion is 2026-12-22.
What conditions does trial NCT06185764 study?
This clinical trial studies the following conditions: Myotonic Dystrophy Type 1 (DM1).
What interventions are being tested in trial NCT06185764?
The interventions under investigation include: Placebo (DRUG), VX-670 (DRUG).
Who is sponsoring clinical trial NCT06185764?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06185764 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy Type 1 (DM1)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06185764's enrollment target sits among peer trials
44 1087th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI